Abstract
Multiple new drugs are being developed to treat acute myeloid leukemia (AML), including novel formulations of traditional chemotherapy-antibody drug conjugates and agents that target specific mutant enzymes. Next-generation sequencing has allowed us to discover the genetic mutations that lead to the development and clinical progression of AML. Studies of clonal hierarchy suggest which mutations occur early and dominate. This has led to targeted therapy against mutant driver proteins as well as the development of drugs such as CPX-351 and SGN-CD33A whose mechanisms of action and efficacy may not be dependent on mutational complexity. In this brief review, wediscuss drugs that may emerge as important for the treatment of AML in the next 10 years.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 71-78 |
| Number of pages | 8 |
| Journal | Blood |
| Volume | 127 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 7 2016 |
ASJC Scopus subject areas
- Hematology
- Biochemistry
- Cell Biology
- Immunology
